Flutamide is used to treat prostate cancer, which acts by blocking the action of exogenous testosterone binding through its androgen receptor. This study was designed and performed to investigate the impact of the Trivedi Effect®-Consciousness Energy Healing Treatment on the structural properties and the isotopic abundance ratio of flutamide using LC-MS and GC-MS spectroscopy. Flutamide sample was divided into control and treated parts. Only the treated flutamide received the Trivedi Effect®-Consciousness Energy Healing Treatment remotely by a famous Biofield Energy Healer, Dahryn Trivedi. The LC-MS spectra of both the samples at retention time (Rt) 3.4 minutes exhibited the mass of the deprotonated molecular ion peak at m/z 275.08 [M-H]-. The peak area of the treated sample was significantly increased by 92.42% compared to the control sample, which indicated that the solubility profile of the treated sample was significantly increased compared to the control sample. The LC-MS based isotopic abundance ratio of PM+1/PM (2H/1H or 13C/12C or 15N/14N or 17O/16O) in the treated flutamide was significantly increased by 59.48% compared with the control sample. The GC-MS based isotopic abundance ratio of PM+1/PM in the treated flutamide sample was increased by 10.39% compared with the control sample. The results indicated that the 13C, 2H, 15N, and 17O contributions from (C11H11F3N2O3)+ to m/z 277 in the treated sample were significantly increased compared with the control sample. The isotopic abundance ratio of PM+1/PM (2H/1H or 13C/12C or 15N/14N or 17O/16O) in the treated flutamide was significantly increased compared to the control sample. The changes in the peak area and isotopic abundance could be due to changes in nuclei possibly through the interference of neutrino via the Trivedi Effect®-Consciousness Energy Healing Treatment. The new form of treated flutamide was formed that might have increase the chemical bond strength, stability, solubility, bioavailability, and efficacy, which could be very much useful to design more efficacious pharmaceutical formulations against prostate cancer, androgen-dependent skin and hair conditions including acne, seborrhea, hirsutism, and scalp hair loss, hyperandrogenism, as well useful for feminizing hormone therapy aimed at transgender women.
